DXCM Stock Overview
A medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
DexCom, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$71.66 |
| 52 Week High | US$132.26 |
| 52 Week Low | US$57.52 |
| Beta | 1.5 |
| 1 Month Change | 5.79% |
| 3 Month Change | -18.13% |
| 1 Year Change | -42.37% |
| 3 Year Change | -29.84% |
| 5 Year Change | -16.07% |
| Change since IPO | 2,341.57% |
Recent News & Updates
Recent updates
Why We're Not Concerned Yet About DexCom, Inc.'s (NASDAQ:DXCM) 25% Share Price Plunge
Apr 04
What Is DexCom, Inc.'s (NASDAQ:DXCM) Share Price Doing?
Mar 06DexCom: Valuation Does Not Factor In Slowing Growth
Mar 04Earnings Miss: DexCom, Inc. Missed EPS By 7.8% And Analysts Are Revising Their Forecasts
Feb 21DexCom, Inc.'s (NASDAQ:DXCM) Intrinsic Value Is Potentially 38% Above Its Share Price
Feb 14DexCom: Fairly Priced In 2025; Why I'm Not Expecting A Share Price Comeback
Jan 17DexCom: Brighter 2025 From Stelo Ramp
Dec 10Is It Too Late To Consider Buying DexCom, Inc. (NASDAQ:DXCM)?
Dec 05Are Investors Undervaluing DexCom, Inc. (NASDAQ:DXCM) By 44%?
Nov 08DexCom Growing Into Its Valuation, But Still No Bargain
Oct 25DexCom, Inc.'s (NASDAQ:DXCM) Price In Tune With Earnings
Oct 21DexCom Q3 Preview: Walking On Eggshells With Its Channel Relationships
Oct 16These 4 Measures Indicate That DexCom (NASDAQ:DXCM) Is Using Debt Safely
Sep 30DexCom: Investors Discounting Long CGM Growth Runway
Sep 19We Like These Underlying Return On Capital Trends At DexCom (NASDAQ:DXCM)
Sep 16DexCom Q2 Earnings: Traditional Market Overreaction
Aug 07Is Now The Time To Look At Buying DexCom, Inc. (NASDAQ:DXCM)?
Jul 26DexCom Q2: Surprising Earnings Miss With Hints Of Competitive Pressures
Jul 26Why Investors Shouldn't Be Surprised By DexCom, Inc.'s (NASDAQ:DXCM) P/E
Jul 12DexCom's ADA Conference Takeaways: Stelo, CGM Tailwinds Still Intact
Jul 03DexCom (NASDAQ:DXCM) Seems To Use Debt Rather Sparingly
Jun 28Calculating The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)
Jun 03Dexcom: Positive Catalysts Ahead To Support Growth
May 13If EPS Growth Is Important To You, DexCom (NASDAQ:DXCM) Presents An Opportunity
May 07DexCom: Attractive Discount After Strong Earnings Results
May 06DexCom Is Pricey For A Reason - Its Growth Story Reflects That
Apr 11DexCom: A Wealth Compounder In Healthcare
Feb 14DexCom: Stelo Stellar Outlook
Jan 17Shareholder Returns
| DXCM | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 4.5% | 4.1% | 4.8% |
| 1Y | -42.4% | 6.5% | 7.8% |
Return vs Industry: DXCM underperformed the US Medical Equipment industry which returned 6.5% over the past year.
Return vs Market: DXCM underperformed the US Market which returned 7.8% over the past year.
Price Volatility
| DXCM volatility | |
|---|---|
| DXCM Average Weekly Movement | 6.8% |
| Medical Equipment Industry Average Movement | 9.3% |
| Market Average Movement | 7.8% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: DXCM has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: DXCM's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 10,250 | Kevin Sayer | www.dexcom.com/global |
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes.
DexCom, Inc. Fundamentals Summary
| DXCM fundamental statistics | |
|---|---|
| Market cap | US$28.10b |
| Earnings (TTM) | US$576.20m |
| Revenue (TTM) | US$4.03b |
48.8x
P/E Ratio7.0x
P/S RatioIs DXCM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DXCM income statement (TTM) | |
|---|---|
| Revenue | US$4.03b |
| Cost of Revenue | US$1.59b |
| Gross Profit | US$2.44b |
| Other Expenses | US$1.86b |
| Earnings | US$576.20m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 01, 2025
| Earnings per share (EPS) | 1.47 |
| Gross Margin | 60.46% |
| Net Profit Margin | 14.29% |
| Debt/Equity Ratio | 116.1% |
How did DXCM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/27 07:47 |
| End of Day Share Price | 2025/04/25 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
DexCom, Inc. is covered by 61 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Francis Mainwaring | Atlantic Equities LLP |
| Anand Vankawala | Avondale Partners |
| Jeffrey Johnson | Baird |